Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events

Shang-Yi Lin; Yi-Wen Chiu; Po-Liang Lu; Shang-Jyh Hwang; Tun-Chieh Chen; Min-Han Hsieh; Yen-Hsu Chen

doi:10.1016/j.jmii.2018.05.003

Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events

J Microbiol Immunol Infect. 2019 Feb;52(1):158-162. doi: 10.1016/j.jmii.2018.05.003. Epub 2018 Jun 2.

Authors

Shang-Yi Lin¹, Yi-Wen Chiu², Po-Liang Lu³, Shang-Jyh Hwang², Tun-Chieh Chen⁴, Min-Han Hsieh⁵, Yen-Hsu Chen⁶

Affiliations

¹ Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; School of Medicine, Graduate Institute of Medicine, Sepsis Research Center, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
² Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
³ Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; School of Medicine, Graduate Institute of Medicine, Sepsis Research Center, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Laboratory Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
⁴ Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
⁵ Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
⁶ Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; School of Medicine, Graduate Institute of Medicine, Sepsis Research Center, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Biological Science and Technology, College of Biological Science and Technology, National Chiao Tung University, Hsin Chu, Taiwan. Electronic address: [email protected].

PMID: 29907535
DOI: 10.1016/j.jmii.2018.05.003

Abstract

The consequences of once-weekly rifapentine plus isoniazid for 3 months (3HP) against latent tuberculosis infections in hemodialysis patients have not been studied before. This is the first study to evaluate the safety and tolerability of 3HP in this population and revealed a completion rate of 65.4%. The therapy was not associated with hepatotoxicity, but with high rates of adverse events (69.2%).

Keywords: 3HP; Hemodialysis; LTBI; Latent tuberculosis; Rifapentine.

MeSH terms

Adult
Aged
Aged, 80 and over
Antitubercular Agents / administration & dosage
Antitubercular Agents / adverse effects
Drug Administration Schedule
Drug Therapy, Combination
Drug-Related Side Effects and Adverse Reactions / epidemiology*
Drug-Related Side Effects and Adverse Reactions / pathology
Female
Humans
Isoniazid / administration & dosage*
Isoniazid / adverse effects
Kidney Failure, Chronic / complications*
Latent Tuberculosis / complications*
Latent Tuberculosis / drug therapy*
Male
Middle Aged
Renal Dialysis*
Rifampin / administration & dosage
Rifampin / adverse effects
Rifampin / analogs & derivatives*
Safety

Substances

Antitubercular Agents
Isoniazid
Rifampin
rifapentine